Sunday 18 October 2026
Export ATOS’s income statement to Excel — free account
Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.
2.91
0.26
+9.81%
Follow ATOS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
6.77 | 5.53 | 4.92 | 5.69 |
Net Debt/EBITDA |
5.62 | 3.62 | 3.23 | 3.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 0.96 | 1.00 | 1.14 | |
Capex/Depreciation |
(1.75) | (1.75) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.70) | (1.22) | (1.11) | (1.08) | |
Cash per Share |
6.03 | 4.81 | 3.69 | 2.94 | |
Shareholders Equity per Share |
5.78 | 4.57 | 3.54 | 3.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.78 | 4.57 | 3.54 | 3.01 | |
Free Cash Flow |
(6.01) | (10.55) | (9.58) | (9.64) | |
Working Capital |
47.45 | 37.36 | 29.21 | 25.56 | |
Capital Expenditures |
(0.01) | (0.01) | — | — | |
Net Current Asset Value |
47.45 | 37.36 | 29.21 | 25.56 | |
| Other line items | |||||
Quick Ratio |
6.32 | 5.02 | 4.27 | 4.81 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.70) | (1.22) | (1.11) | (1.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.55 | 2.49 | 1.87 | 1.99 | |
Average Inventory |
— | 1.55 | — | 1.55 | |
Average Assets |
68.74 | 62.03 | 54.35 | 48.40 | |
Average Common Equity |
61.73 | 55.42 | 47.90 | 42.26 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 2 Oct 2026